+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 108 Pages
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309800
Global Neurological Biomarkers for Alzheimers and Parkinsons Diseases Market to Reach $8.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 8.7% over the period 2020-2027.



The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.1% CAGR

The Neurological Biomarkers for Alzheimers and Parkinsons Diseases market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Select Competitors (Total 46 Featured):
  • AbaStar MDx
  • Abbott Laboratories
  • Abiant
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Athena Diagnostics
  • Banyan Biomarkers
  • Bio-Rad Laboratories
  • Diagenic ASA
  • Immunarray Pvt. Ltd.
  • Myriad RBM
  • Proteome Sciences
  • ProteoSys AG
  • Psynova Neurotech
  • Qiagen
  • Quanterix Corporation
  • Thermo Fisher Scientific
Frequently Asked Questions about the Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases

What is the estimated value of the Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases?

The Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases was estimated to be valued at $4.6 Billion in 2020.

What is the growth rate of the Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases?

The growth rate of the Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases is 8.8%, with an estimated value of $8.3 Billion by 2027.

What is the forecasted size of the Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases?

The Global Market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases is estimated to be worth $8.3 Billion by 2027.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS
  • UNITED STATES
  • Table 4: USA Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 5: USA Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CANADA
  • Table 6: Canada Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 7: Canada Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • JAPAN
  • Table 8: Japan Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 9: Japan Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CHINA
  • Table 10: China Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 11: China Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • EUROPE
  • Table 12: Europe Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 13: Europe Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 14: Europe 15-Year Perspective for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
  • Table 15: France Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 16: France Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • GERMANY
  • Table 17: Germany Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 18: Germany Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ITALY
  • Table 19: Italy Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: Italy Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
  • Table 21: UK Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 22: UK Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
  • Table 23: Rest of Europe Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: Rest of Europe Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
  • Table 25: Asia-Pacific Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Asia-Pacific Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF WORLD
  • Table 27: Rest of World Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: Rest of World Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

IV. COMPETITION
  • Total Companies Profiled: 46